Andarine (S-4): The Vision-Side-Effect SARM Behind Selective Androgen Research

Andarine, also known as S-4 and GTx-007, is an experimental selective androgen receptor modulator (SARM). It is often discussed online in connection with muscle definition and “cutting” phases. But behind those claims is a more important story: Andarine was an investigational drug candidate, it is not approved for human use, and its development became associated with visual disturbances.

This spotlight separates the research history from gym folklore, explains what is known about the vision concern, and outlines why safety and Australian regulatory status matter.

Video placeholder 1: Andarine (S-4) explained: what the research can, and cannot, tell us

What is Andarine, and why was it developed?

Andarine is a nonsteroidal compound designed to interact with the androgen receptor. A protein that responds to hormones such as testosterone. It was developed by GTx, Inc. as part of research into whether a compound could encourage certain androgen-related effects in muscle and bone while reducing some effects in other tissues.

Researchers explored Andarine in connection with muscle wasting, bone loss and osteoporosis, and benign prostatic hypertrophy (also called benign prostatic hyperplasia, or BPH. A non-cancerous enlargement of the prostate). These were research aims, not approved treatments or proven clinical benefits. GTx’s company filings document early-stage human testing, but they do not establish Andarine as an effective or safe treatment for these conditions. GTx SEC filing

The word selective can sound like a safety guarantee. It is not. It describes the goal of influencing some tissues differently from others, not a promise that a compound acts only where intended.

How selective androgen receptor modulation works

Think of the androgen receptor as a lock inside a cell. Androgens are keys that can activate it. Once activated, the receptor can influence gene activity involved in processes such as muscle and bone maintenance.

A SARM is designed to engage that lock in a way that may produce different responses in different tissues. You can picture it like a dimmer switch: the intended setting might differ between muscle, bone and prostate tissue. But biology is not a neatly wired building. The effect can depend on the tissue, dose, individual biology and other factors, and selective activity does not eliminate unwanted effects.

Andarine’s proposed appeal was this potential tissue selectivity: support for anabolic activity in muscle and bone with less prostate stimulation than conventional anabolic steroids. That was a research rationale, not proof that it provides safe muscle growth or protects the prostate in people.

Why it is associated with “hardening” and cutting

In bodybuilding discussions, Andarine is often associated with a lean, “hard” appearance or a cutting phase. These descriptions largely come from anecdotal reports and marketing claims. They should not be mistaken for reliable clinical evidence that Andarine helps people lose fat, preserve muscle, or achieve a particular physique.

In plain terms: a popular claim is not the same as a demonstrated result. Early drug development does not establish safety or effectiveness for recreational use, and a product labelled “research use only” has not thereby been shown suitable for people.

For a broader introduction to SARMs, see our related SARM product information on Ostarine and Ligandrol. These are product listings, not clinical comparisons or recommendations.

The vision concern: the detail you should not overlook

Andarine stands out among SARMs because of reports of visual disturbances, including yellow- or green-tinged vision, changes in colour perception and difficulty seeing in low light. The concern is not simply internet rumour: later scientific literature describes visual adverse effects as a reason Andarine’s early clinical development was stopped. Scientific paper on S-4 detection

However, the precise mechanism is not firmly established. Online explanations sometimes state that Andarine’s affinity for ocular receptors definitively causes yellow vision. That certainty goes beyond what the available evidence supports. The reported visual effects have been linked to possible actions in retinal or other visual pathways, but a specific ocular-receptor mechanism has not been confirmed.

Do not dismiss changes in vision as a routine or harmless trade-off. If you have taken a product labelled Andarine and notice altered colour vision, night-vision problems or any other change in sight, stop trying to self-manage the issue and seek prompt medical advice. Sudden or severe vision changes warrant urgent assessment.

Video placeholder 2: SARMs and safety: why “selective” does not mean risk-free

Testosterone suppression and post-cycle considerations

Androgen signalling is part of a wider hormonal feedback system. When the body detects outside androgen-like activity, it may reduce its own signalling, a bit like a thermostat turning down the heating when it senses extra warmth. With SARMs, this raises concern about suppression of the body’s natural testosterone production and other hormone changes.

The extent and duration of any effect can vary. Do not assume that everyone will recover on the same timeline, or that an online “post-cycle therapy” (PCT) plan is safe or necessary. Medicines sometimes discussed as PCT are not risk-free fixes, and using them without medical oversight can add further complications.

If you have used a SARM or are worried about hormone-related symptoms, speak with a qualified clinician. They can consider your symptoms, medical history and appropriate laboratory testing, then advise on follow-up. For related reading on hormonal signalling, see our Gonadorelin and Triptorelin research article. It is educational content, not a self-treatment plan.

Safety, liver health and product claims

SARMs are not approved medicines in Australia, and an online product’s contents and quality may not match what a buyer expects. The U.S. Food and Drug Administration also warns that SARMs are unapproved and has identified serious potential risks associated with the class, including liver injury and cardiovascular concerns. Those class-level warnings should not be mistaken for a precise estimate of risk from Andarine specifically. FDA information on SARMs

A “liver support” supplement cannot make an unapproved drug safe or prevent all possible harm. Our Organ Guard product page describes the product, but its claims are not proof that it prevents Andarine-related liver injury. If you have used a SARM and feel unwell, contact a clinician rather than trying to treat possible liver effects with supplements.

Australian rules and sport status

The regulatory position is clear: Andarine is not approved for human use. A “research chemical” label does not turn it into an approved medicine or confirm that it is safe for self-administration. Australian rules for importing and accessing unapproved therapeutic goods can be complex; check current guidance with the Therapeutic Goods Administration and relevant authorities rather than relying on a seller’s assurances.

For athletes, the 2026 World Anti-Doping Agency (WADA) Prohibited List expressly names Andarine among prohibited SARMs. It is prohibited at all times, both in and out of competition. WADA 2026 Prohibited List

The practical takeaway

Andarine is notable not because it is a proven shortcut, but because it illustrates the gap between an attractive research idea and a safe, approved treatment. Its proposed tissue selectivity did not remove concerns about vision, hormonal effects or uncertain product quality.

Stay evidence-led. Don’t self-treat. Ask a clinician before acting on claims about SARMs, hormone recovery or liver protection.

For reference, WL Australia’s Andarine/S-4 product page identifies the item as a research product, not for human use. Product information is not medical advice, and the listing should not be taken as a recommendation to use it.